Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
复制标题
DOI：
10.1532/ijh97.04058
复制
发表时间：
2004-10-01
影响因子：
2.1
通讯作者：
Takatsuki, K
中科院分区：
文献类型：
--
作者：
Kunitomi, A;Konaka, Y;Takatsuki, K
难治性自身免疫性溶血性贫血（AIHA）与相当高的死亡率相关。白细胞介素6（IL-6）已被报道在AIHA的发病机制中发挥作用。本报告描述了一个AIHA患者谁是成功地与人源化抗人IL-6受体（IL-6 R）单克隆抗体（MoAb）治疗。他经历了危及生命的AIHA，并接受了皮质类固醇、硫唑嘌呤、环磷酰胺、环孢菌素A、美法仑、血浆置换和脾脏照射的常规治疗。然而，患者的症状和实验室数据并未显示出充分的改善。由于他的血清IL-6水平升高，我们试图通过使用人源化抗IL-6 R单克隆抗体（MRA）来阻断IL-6信号传导。每2周给予8 mg/kg MRA，血清血红蛋白水平逐渐升高，并在4个月内恢复正常。MRA治疗2年后，疾病活动得到良好控制，无不良反应。抗IL-6 R单克隆抗体有望成为AIHA的一种新的有效治疗药物。(C)2004年日本血液学会。
Refractory autoimmune hemolytic anemia (AIHA) is associated with considerable rates of mortality. Interleukin 6 (IL-6) has been reported to play a role in the pathogenesis of AIHA. This report describes a patient with AIHA who was successfully treated with a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody (MoAb). He had experienced life-threatening AIHA and had received conventional therapy with corticosteroids, azathioprine, cyclophosphamide, cyclosporin A, melphalan, plasma exchange, and irradiation to his spleen. However, the patient's symptoms and laboratory data did not show a sufficient improvement. Because his serum IL-6 level was elevated, we attempted to block IL-6 signaling by using a humanized anti-IL-6R MoAb, MRA. With 8 mg/kg of MRA administration every 2 weeks, the serum hemoglobin level gradually increased and normalized within 4 months. After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA. (C) 2004 The Japanese Society of Hematology.